全球前列腺癌临床试验中阿片类药物使用差异
该研究基于美国FDA内部数据库,纳入2008年后启动的8项转移性前列腺癌国际3期随机临床试验,共9670例患者,比较全球不同地区阿片类药物使用情况,发现东欧和亚洲患者使用阿片类药物的可能性显著低于北美患者,且该差异在基线中高度疼痛患者中仍存在。
要点
- 东欧和亚洲前列腺癌患者使用阿片类药物的几率显著低于北美患者。
- 在基线中高度疼痛患者中,地区差异依然存在。
- 国际临床试验若以阿片类药物使用时间为终点,需考虑地区差异。
核心结论
- 尽管在临床试验标准化条件下,阿片类药物使用仍存在全球地区差异,提示国际临床试验设计需考虑此变异。
研究设计与样本
- 国际3期随机临床试验汇总分析,纳入2008年1月1日后启动的8项转移性前列腺癌试验,来自46个国家,共9670例意向治疗患者。
主要发现
- 与北美患者相比,东欧患者使用阿片类药物的调整比值比为0.19(95% CI 0.16-0.22),亚洲患者为0.31(95% CI 0.25-0.38)。
- 在基线中高度疼痛患者中,东欧调整比值比为0.16(95% CI 0.12-0.22),亚洲为0.47(95% CI 0.29-0.79)。
- 北美内部,美国与加拿大阿片类药物使用率相似,调整比值比为1.13(95% CI 0.93-1.37)。
临床怎么用
- 在涉及阿片类药物使用终点或疼痛管理的国际临床试验中,应考虑地区间阿片类药物使用差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Regional variation in opioid use may be attenuated when pharmaceutical-sponsored trials include care that is often standardized by protocols. Understanding such variation is important for global trials that sometimes include time to opioid use as an end point. OBJECTIVE: To identify whether regional and country-level variation in opioid use exists among prostate cancer clinical trials across the world. DESIGN, SETTING, AND PARTICIPANTS: International phase 3 randomized clinical trials with patients with metastatic prostate cancer and initiation from January 1, 2008, or later were identified through internal databases of the US Food and Drug Administration. Data of patients in the intention-to-treat population from each trial were pooled. Descriptive and regression analyses of the collected data were conducted from September 2018 to February 2019. EXPOSURES: Cancer therapy. MAIN OUTCOMES AND MEASURES: Opioid use data were from concomitant medications reported in the database for each trial. Logistic regression models, descriptive statistics, and χ2 tests were used to compare opioid use across world regions while adjusting for patient age, presence of visceral disease, bony disease, and baseline Eastern Cooperative Oncology Group Performance Status score and pain score. RESULTS: In total, 9670 patients (mean [SD] age of 69.2 [8.3] years) from 8 prostate cancer clinical trials in 46 countries were included. Patients in Eastern Europe (adjusted odds ratio [AOR], 0.19; 95% CI, 0.16-0.22) and Asia (AOR, 0.31; 95% CI, 0.25-0.38) were less likely to use opioids compared with patients in North America. These findings held even when the analysis was restricted to patients who reported moderate to high pain levels at baseline (Eastern Europe: AOR, 0.16 [95% CI, 0.12-0.22]; Asia: AOR, 0.47 [95% CI, 0.29-0.79]). Within North America, rates of opioid use were similar between the United States and Canada (AOR, 1.13; 95% CI, 0.93-1.37). CONCLUSIONS AND RELEVANCE: This study found that, despite the clinical trial setting, opioid use appeared to vary by world regions, suggesting that this variability should be considered in international clinical trials.
引用
- Roydhouse JK, Suzman DL, Menapace LA, et al. Global Variation in Opioid Use in Prostate Cancer Trials. JAMA Oncol. 2019. PMID: 31513232. doi:10.1001/jamaoncol.2019.2971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。